In fact, all clinicopathological and immunophenotypic features of primary CRISPRMLL-AF4+ ALL were maintained in secondary recipients, including CNS disease (Supplementary Table 2). This evidence concerns the gene AFF1 and acute lymphoblastic leukemia.